Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Assessment of worldwide acute kidney injury epidemiology in neonates: Design of a retrospective cohort study

Producción científica: Articlerevisión exhaustiva

117 Citas (Scopus)

Resumen

Introduction: Acute kidney injury (AKI) affects ~30% of hospitalized neonates. Critical to advancing our understanding of neonatal AKI is collaborative research among neonatologists and nephrologists. The Neonatal Kidney Collaborative (NKC) is an international, multidisciplinary group dedicated to investigating neonatal AKI. The AWAKEN study (Assessment of Worldwide Acute Kidney injury Epidemiology in Neonates) was designed to describe the epidemiology of neonatal AKI, validate the definition of neonatal AKI, identify primary risk factors for neonatal AKI, and investigate the contribution of fluid management to AKI events and short-term outcomes. Methods and analysis: The NKC was established with at least one pediatric nephrologist and neonatologist from 24 institutions in 4 countries (USA, Canada, Australia, and India). A Steering Committee and four subcommittees were created. The database subcommittee oversaw the development of the web-based database (MediData Rave™) that captured all NICU admissions from 1/1/14 to 3/31/14. Inclusion and exclusion criteria were applied to eliminate neonates with a low likelihood of AKI. Data collection included: (1) baseline demographic information; (2) daily physiologic parameters and care received during the first week of life; (3) weekly "snapshots"; (4) discharge information including growth parameters, final diagnoses, discharge medications, and need for renal replacement therapy; and (5) all serum creatinine values. Ethics and dissemination: AWAKEN was proposed as human subjects research. The study design allowed for a waiver of informed consent/parental permission. NKC investigators will disseminate data through peer-reviewed publications and educational conferences. Discussion: The purpose of this publication is to describe the formation of the NKC, the establishment of the AWAKEN cohort and database, future directions, and a few "lessons learned." The AWAKEN database includes ~325 unique variables and > 4 million discrete data points. AWAKEN will be the largest, most inclusive neonatal AKI study to date. In addition to validating the neonatal AKI definition and identifying risk factors for AKI, this study will uncover variations in practice patterns related to fluid provision, renal function monitoring, and involvement of pediatric nephrologists during hospitalization. The AWAKEN study will position the NKC to achieve the long-term goal of improving the lives, health, and well-being of newborns at risk for kidney disease.

Idioma originalEnglish
Número de artículo68
PublicaciónFrontiers in Pediatrics
Volumen4
N.ºJUL
DOI
EstadoPublished - jul 1 2016

Nota bibliográfica

Publisher Copyright:
© 2016 Jetton, Guillet, Askenazi, Dill, Jacobs, Kent, Selewski, Abitbol, Kaskel, Mhanna, Ambalavanan, Charlton and the Neonatal Kidney Collaborative.

Financiación

The Cincinnati Children’s Hospital Center for Acute Care Nephrology (SLG, Director) provided funding to create and maintain the AWAKEN Medidata Rave electronic database. CA was supported by the Micah Batchelor Foundation. AAA and CJR were supported by the Section of Pediatric Nephrology, Department of Pediatrics, Texas Children’s Hospital. DA and NA are supported by the Pediatric and Infant Center for Acute Nephrology (PICAN), which is sponsored by Children’s of Alabama and the University of Alabama at Birmingham’s School of Medicine, Department of Pediatrics and Center for Clinical and Translational Science (CCTS) under award number UL1TR00165. PDB, TTC, JGJ, and JMK were supported by the University of Iowa Institute for Clinical and Translational Science. JRC and JRS Conflict of Interest Statement: David Askenazi serves on the speaker board for BAXTER, and the AKI Foundation. Stuart L. Goldstein receives grant funding from Baxter Healthcare and is a consultant for Baxter, Bellco, Inc., Akebia, Inc., AM Pharma, Inc., and Astute Medical. Jonathan M. Klein is a consultant for Draeger Medical. Juan C. Kupferman is on the speaker’s Bureau and consultant for Alexion Pharmaceuticals. Subrata Sarkar is a consultant for GW Research Ltd, Cambridge, UK.

FinanciadoresNúmero del financiador
University of Alabama at Birmingham’s School of Medicine, Department of Pediatrics and Center for Clinical and Translational Science
Texas Children's Hospital
Baxter Healthcare Corporation
Indiana Clinical and Translational Sciences Institute
Astute Medical Incorporated
Center for Clinical and Translational Science, University of UtahUL1TR00165
Department of Pediatrics, University of Florida
Batchelor Foundation
Children's of Alabama

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Pediatrics, Perinatology, and Child Health

    Huella

    Profundice en los temas de investigación de 'Assessment of worldwide acute kidney injury epidemiology in neonates: Design of a retrospective cohort study'. En conjunto forman una huella única.

    Citar esto